Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 3Phase 1 3Phase 3 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Pancreatic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 3Tirzepatide 2Paclitaxel 2Metformin 2Carboplatin 2tislelizumab 1olaparib 1niraparib 1montelukast 1Taxes 1Tablets 1Radiotherapy, Intensity-Modulated 1Progesterone 1Pafolacianine 1Morphine 1Laparotomy 1Hysterectomy 1Fluorescein 1Ezetimibe 1Dasatinib 1Biopsy 1Atorvastatin 1Anti-Inflammatory Agents, Non-Steroidal 1Anesthesia, Local 1Anesthesia, General 1Anesthesia, Conduction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Neoplasms × olaparib × Clear all
NCT05320757 2025-06-11

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

The University of Hong Kong

Phase EARLY_PHASE1 Completed
20 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡